Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long‑term remission

Terao, Toshiki; Yuda, Junichiro; Yamauchi, Nobuhiko; Guo, Yong-Mei; Shimada, Kaoru; Sugano, Masato; Ishii, Genichiro; Minami, Yosuke

doi:10.3892/mco.2021.2287

Cited by 4 publications

(3 citation statements)

References 13 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, brentuximab vedotin, an anti-CD30 antibody, has been used to treat Hodgkin lymphoma and CD30-positive lymphoma[ 9 , 26 , 27 ]. Pembrolizumab, an anti-PD-L1 monoclonal antibody, is also used for patients with refractory GZL[ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report

Hōjō¹,

Nagasaki²,

Mihara³

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (BCLu-DLBCL/cHL), also referred to as gray zone lymphoma (GZL), is known to share features with cHL and DLBCL. However, GZL is often difficult to diagnose. There is no consensus regarding the optimal therapeutic regimen. Most reported cases of GZL have been in Caucasian and Hispanic individuals, and its incidence is lower in African-American and Asian populations, including the Japanese population. CASE SUMMARY A 69-year-old female presented at our hospital with a growing mass on the right side of her neck. An elastic, soft mass measuring 9 cm × 6 cm was palpable in the right cervical region. Laboratory analyses showed pancytopenia, increased serum lactate dehydrogenase levels, and markedly increased levels of soluble interleukin-2 receptor. Enhanced computed tomography (CT) and fluorodeoxyglucose positron emission tomography (PET)/CT revealed multiple lesions throughout her body. She was diagnosed with GZL based on the characteristic pathological findings, the immunophenotype [CD20+, PAX5+, OCT2+/BOB1 (focal+), CD30+, CD15-], and the strong positive expression of neoplastic programmed cell death protein ligand 1 (PD-L1) in her lymphoma cells. The lymphoma was stage IV according to the Lugano classification and high-risk according to the International Prognostic Index for aggressive non-Hodgkin lymphoma. The patient received cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R-CHOP) chemotherapy because the tumor cells were CD20+. She has remained in complete remission for 3 years. CONCLUSION GZL was diagnosed based on histopathology and immunophenotyping with ancillary PD-L1 positivity. R-CHOP chemotherapy was an effective treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report

Hōjō¹,

Nagasaki²,

Mihara³

2022

WJCC

View full text Add to dashboard Cite

show abstract

“…Based on the results observed in PMBL [27], a very recent publication has reported that the combination of brentuximab vedotin (BV), and nivolumab is effective in approximately 70% of patients with R/R MGZL [28]. BV is an anti-CD30 humanised monoclonal antibody conjugated with monomethyl auristatin E, and the expression of CD30 by tumour cells represents the rationale of its usage [28,29]. BV was found to be effective also as maintenance after ASCT in R/R MGZL [29].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

“…BV is an anti-CD30 humanised monoclonal antibody conjugated with monomethyl auristatin E, and the expression of CD30 by tumour cells represents the rationale of its usage [28,29]. BV was found to be effective also as maintenance after ASCT in R/R MGZL [29]. In addition to the target effect, BV may also induce an immunogenic environment contributing to the depletion of regulatory T-cells that can potentiate the effect of immune-checkpoint inhibitors, such as nivolumab [28].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Mediastinal Gray-Zone Lymphoma: Still an Open Issue

Pileri

Tabanelli

Chiarle

et al. 2023

Hemato

View full text Add to dashboard Cite

The concept of gray-zone lymphoma (GZL) has been progressively refined since its introduction in the literature in 1998. For several years, it was applied to a rather broad spectrum of conditions, posing the problem of the differential diagnosis between any type of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma, with special reference to primary mediastinal forms (PMBL). Officially recognised as a provisional entity in the 4th and revised 4th editions of the WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues with the term “B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma”, it was limited to tumours showing either morphologic features reminiscent of classic HL (CHL) but carrying a complete B-cell phenotype or conversely provided with a PMBL morphology yet revealing CHL phenotypic characteristics. The definition of GZL has been further revised in the recently published International Lymphoma Classification and 5th edition of the WHO Classification of Haematolymphoid Tumours, which have limited it to mediastinal neoplasms (MGZL) based on emerging molecular evidence. The aim of this review is to critically discuss the issue of MGZL, as well as in light of the suboptimal response to current therapies.

show abstract

Withdrawn: A Difficult Entity for Pathologists and Clinicians: Gray Zone Lymphoma

Paydaş

2023

Pathology - Research and Practice

View full text Add to dashboard Cite

Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long‑term remission

Cited by 4 publications

References 13 publications

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report

Mediastinal Gray-Zone Lymphoma: Still an Open Issue

Withdrawn: A Difficult Entity for Pathologists and Clinicians: Gray Zone Lymphoma

Contact Info

Product

Resources

About